Aleix Prat, Director of the Clínic Barcelona Comprehensive Cancer Center, shared on LinkedIn:
“A major milestone for cancer research and innovation at Clínic Barcelona!
We have received regulatory approval and successfully completed the site initiation visit for ARI-HER2, a novel academic CAR-T cell therapy developed at the Clínic Barcelona Comprehensive Cancer Centre (4CB).
This achievement is the result of years of collaborative work between Dr. Sonia Guedan, Dr. Manel Juan, and my clinical and translational research team, with the support of Dr. Julio Delgado, Head of the Immuno-Oncology Unit.
We hope to treat our first patient with HER2-positive metastatic breast cancer very soon! This trial will be performed in close collaboration with SOLTI cancer research, 12 de Octubre University Hospital and University of Navarra Clinic.
A major step toward bringing CAR-T therapies to solid tumors.
Huge thanks to Spanish Association Against Cancer for their invaluable support to make this a reality!
From our labs to our patients. This is what translational research is all about!”
You can also read: Hidden Basal-Like Cells in Luminal Breast Cancer: Nature Study Reveals New Epigenetic Signals of Recurrence
